Early Infantile Developmental and Epileptic Encephalopathy (EIDEE)

Early infantile developmental and epileptic encephalopathy (EIDEE) is a severe epilepsy syndrome beginning in the first months of life, characterised by frequent seizures, a markedly abnormal EEG and major developmental impairment. It replaces older attempts to force every very-early severe epilepsy into narrowly defined historical syndromes.

EIDEE is an electroclinical syndrome, not one disease. Many different genetic, structural and metabolic causes can produce it.

Why the modern term matters

Older classifications used labels such as Ohtahara syndrome and early myoclonic encephalopathy. In practice, many infants do not fit neatly into one of those historical boxes.

The ILAE introduced EIDEE to better capture a severe early-onset phenotype while allowing the underlying aetiology to be described separately.

Age at onset

Seizures begin very early, often in the neonatal period or first few months of life.

Some infants show neurological or developmental abnormalities even before seizures begin, indicating that the underlying disorder is already affecting brain development.

Seizure types

Tonic seizures are common, but focal seizures, myoclonic seizures and other types can occur.

Seizures may be frequent, occur in clusters and prove difficult to control.

EEG

The EEG background is severely abnormal. A suppression-burst pattern can occur, with alternating periods of high-amplitude epileptiform activity and low-voltage suppression.

Other infants show multifocal epileptiform activity or severe background slowing.

Developmental and epileptic encephalopathy

The term acknowledges two contributors to impairment.

The underlying genetic, structural or metabolic disorder can directly impair development, while frequent seizures and severe epileptiform activity can add further developmental burden.

Causes

Genetic causes include variants in many genes involved in ion channels, synaptic transmission, neuronal development and gene regulation.

Examples include KCNQ2, STXBP1, SCN2A, SCN8A, KCNT1, CDKL5 and others. Structural brain malformations and metabolic disorders can also cause an EIDEE phenotype.

Why rapid diagnosis matters

Some causes have treatment implications. Vitamin B6-dependent epilepsies, GLUT1 deficiency, selected channelopathies and structural lesions can require very different management.

Rapid genetic and metabolic diagnosis can therefore move care beyond repeated empirical medication trials.

MRI

MRI is important to identify cortical malformations, destructive brain lesions and other structural causes.

A normal MRI does not rule out EIDEE because many genetic causes do not produce a visible structural lesion.

Genetic testing

Because of the large number of possible genes, broad genomic testing is often more efficient than sequential single-gene testing.

Rapid exome or genome sequencing is increasingly used in neonatal and intensive-care settings where available.

Metabolic testing

Selected metabolic tests are important, particularly when there are biochemical abnormalities, unusual movements, systemic features or a potentially treatable metabolic epilepsy.

Vitamin B6-dependent epilepsy should be considered in severe unexplained neonatal seizures because targeted treatment can be transformative.

Treatment

There is no universal EIDEE treatment because therapy depends heavily on the underlying cause.

Broad-spectrum and focal antiseizure medicines may be used according to seizure type, but genetic or metabolic diagnosis can change which treatment is preferred.

Precision treatment

In some channelopathies, variant mechanism matters. For example, selected early SCN2A or KCNQ2 gain-of-function epilepsies may respond better to sodium-channel-blocking medicines.

This is specialist precision medicine and should not be interpreted as a universal rule for every variant in those genes.

Ketogenic dietary therapy

Ketogenic therapy may be considered in drug-resistant EIDEE, especially when the underlying metabolic mechanism suggests likely benefit.

It is not appropriate for every metabolic disorder and requires specialist supervision.

Evolution into later syndromes

Some infants later develop epileptic spasms, Lennox–Gastaut syndrome or another recognisable epilepsy phenotype.

Syndrome evolution reflects both the changing brain and the underlying cause.

Development and prognosis

Developmental impairment is usually substantial, but severity varies by aetiology.

Outcome should therefore not be predicted from the EIDEE label alone. A precise cause often provides more useful prognostic information.

Worldwide access

EIDEE exposes one of the largest global diagnostic inequalities in epilepsy. Accurate diagnosis may require continuous EEG, MRI, metabolic testing and rapid genomics.

Where these are unavailable, clinicians may have to manage a severe epilepsy syndrome without knowing the underlying mechanism, limiting access to precision treatment.

The central point

EIDEE is a severe early-life epilepsy syndrome, not a single disease. The most important next question after recognising the syndrome is often: what is causing it, and is that cause specifically treatable?

Sources

Medical note: severe seizures in the first months of life require specialist investigation because some causes have urgent targeted treatments.

Evidence checked: September 2026.